Page last updated: 2024-10-21

pd 173074 and Neoplasms

pd 173074 has been researched along with Neoplasms in 7 studies

Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Research Excerpts

ExcerptRelevanceReference
"Genetically defined cancer subsets, irrespective of tissue type, predict response to kinase inhibitors, and provide an important preclinical model to guide early clinical applications of novel targeted inhibitors."1.34Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. ( Archibald, H; Dowell, L; Drew, L; Erlander, MG; Gray, NS; Greninger, P; Haber, DA; Hanke, JH; Iafrate, AJ; Lamb, J; Lee, D; Ma, XJ; Maheswaran, S; McDermott, U; Montagut, C; Njauw, CN; Raudales, R; Rothenberg, SM; Settleman, J; Sharma, SV; Sordella, R; Supko, JG; Tam, A; Tsao, H; Ulkus, LE, 2007)

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's5 (71.43)24.3611
2020's1 (14.29)2.80

Authors

AuthorsStudies
McDermott, U1
Sharma, SV1
Dowell, L1
Greninger, P1
Montagut, C1
Lamb, J1
Archibald, H1
Raudales, R1
Tam, A1
Lee, D1
Rothenberg, SM1
Supko, JG1
Sordella, R1
Ulkus, LE1
Iafrate, AJ1
Maheswaran, S1
Njauw, CN1
Tsao, H1
Drew, L1
Hanke, JH1
Ma, XJ1
Erlander, MG1
Gray, NS1
Haber, DA1
Settleman, J1
Ahmed, SM1
Ragunathan, P1
Shin, J1
Peter, S1
Kleissle, S1
Neuenschwander, M1
Schäfer, R1
Kries, JPV1
Grüber, G1
Dröge, P1
Patel, A1
Tiwari, AK1
Chufan, EE1
Sodani, K1
Anreddy, N1
Singh, S1
Ambudkar, SV1
Stephani, R1
Chen, ZS1
Herrera-Abreu, MT1
Pearson, A1
Campbell, J1
Shnyder, SD1
Knowles, MA1
Ashworth, A1
Turner, NC1
Oneyama, C1
Ikeda, J1
Okuzaki, D1
Suzuki, K1
Kanou, T1
Shintani, Y1
Morii, E1
Okumura, M1
Aozasa, K1
Okada, M1
Chell, V1
Balmanno, K1
Little, AS1
Wilson, M1
Andrews, S1
Blockley, L1
Hampson, M1
Gavine, PR1
Cook, SJ1
Kumar, SB1
Narasu, L1
Gundla, R1
Dayam, R1
J A R P, S1

Reviews

1 review available for pd 173074 and Neoplasms

ArticleYear
Fibroblast growth factor receptor inhibitors.
    Current pharmaceutical design, 2013, Volume: 19, Issue:4

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Drug Design; Humans; Neoplasms; Neovascular

2013

Other Studies

6 other studies available for pd 173074 and Neoplasms

ArticleYear
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
    Proceedings of the National Academy of Sciences of the United States of America, 2007, Dec-11, Volume: 104, Issue:50

    Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor

2007
The FGFR inhibitor PD173074 binds to the C-terminus of oncofetal HMGA2 and modulates its DNA-binding and transcriptional activation functions.
    FEBS letters, 2023, Volume: 597, Issue:15

    Topics: Adult; Chromatin; DNA; HMGA2 Protein; Humans; Neoplasms; Receptors, Fibroblast Growth Factor; Transc

2023
PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells.
    Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:1

    Topics: Adenosine Triphosphate; Affinity Labels; Allosteric Regulation; Antineoplastic Agents; ATP Binding C

2013
Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer.
    Cancer discovery, 2013, Volume: 3, Issue:9

    Topics: Animals; Cell Line, Tumor; Dasatinib; ErbB Receptors; Gefitinib; Heterografts; High-Throughput Scree

2013
MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways.
    Oncogene, 2011, Aug-11, Volume: 30, Issue:32

    Topics: Animals; Cell Line; Cell Proliferation; Cell Transformation, Neoplastic; Cells, Cultured; Cluster An

2011
Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.
    Oncogene, 2013, Jun-20, Volume: 32, Issue:25

    Topics: Antineoplastic Agents; Benzamides; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Fe

2013